AI and DTB, drug safety, tirzepatide, and lecanemab for Alzheimer's disease

In this podcast accompanying the August issue of DTB ( ), David Phizackerley (DTB Editor) is joined by James Cave (former DTB Editor-in-Chief). David and James discuss an editorial generated by artificial intelligence (AI) ( ) which looks at the role of AI in publishing. They talk about a DTB Forum article ( ) that explores some of the practical problems of implementing drug safety alerts. A DTB Select article ( ) provides an overview of a double-blind, randomised, placebo-controlled trial of tirzepatide for weight reduction in people without diabetes. They finish by reviewing the main article ( ) that provides an overview of the evidence for lecanemab for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease. Link BMJ policy on AI use: Please

You can listen to AI and DTB, drug safety, tirzepatide, and lecanemab for Alzheimer's disease online on Radio and Podcast. Open the player on this page to stream the available audio.

AI and DTB, drug safety, tirzepatide, and lecanemab for Alzheimer's disease is an episode from DTB podcast by BMJ Group.

This episode is 38:47 long.

This episode was published on Jul 31, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from DTB podcast when more episodes are available from the podcast feed.